Smoking and infertility: a committee opinion

The Practice Committee of the American Society for Reproductive Medicine
American Society for Reproductive Medicine, Birmingham, Alabama

Approximately 30% of women of reproductive age and 35% of men of reproductive age in the United States smoke cigarettes. Substantial harmful effects of cigarette smoke on fecundity and reproduction have become apparent but are not generally appreciated. This document replaces the 2008 ASRM Practice Committee document of the same name. (Fertil Steril® 2012;98:1400–6. ©2012 by American Society for Reproductive Medicine.)

Discuss: You can discuss this article with its authors and with other ASRM members at http://fertstertforum.com/goldsteinj-smoking-infertility-committee-opinion/

REVIEW METHODS

To evaluate the impact of smoking on fertility outcome, the Committee searched the MEDLINE site up to January 2012. We used combinations of medical subject headings “smoking,” “tobacco,” “oocyte,” “sperm,” “fertility,” “pregnancy,” “complications,” and “conception.” The reference lists of relevant articles were reviewed for further reports. Only English-language articles were selected, and the search was restricted to published articles. Review articles were included. The relevance of included articles was assessed by one committee member, with subsequent consultation by the committee as a whole. Because the majority of the studies were case series and reviews, methods of aggregation and analysis were limited to summarization. The updated document was revised by the Practice Committee after discussion of additions and deletions.

Approximately 30% of women of reproductive age and 35% of men of reproductive age in the United States smoke cigarettes. Substantial harmful effects of cigarette smoke on fecundity and reproduction have become apparent but are not generally appreciated. In addition there are recognized harmful effects from passive and sidestream smoking that are hard to capture. A survey of 388 female employees of a Connecticut hospital revealed that the major deleterious health effects of smoking are widely recognized. However, the majority of the women surveyed, including female health-care providers, were unfamiliar with the reproductive risks associated with smoking (Table 1) (1).

This document reviews the evidence linking cigarette smoking with reproductive hazards for both females and males. Health care providers who educate their patients about the risks of smoking will increase the likelihood that their patients can stop smoking (2, 3).

Assessment of Causality

Overall, the literature strongly supports an association between cigarette smoking and infertility. Two systematic reviews have analyzed the evidence to support a causal relationship (4, 5).

Both concluded that causality cannot be excluded but would require more rigorous empiric evidence. The following briefly summarizes the criteria for causality and the status of existing information (4, 5).

Strength: The association between smoking and increased risk for infertility is statistically significant but not particularly strong in most studies.

Consistency: The association between smoking and decreased fertility is generally quite consistent across most studies.

Dose Response: A number of studies have demonstrated a dose-dependent adverse effect of smoking on fertility (6–8). Even at one-half pack per day use, female cigarette consumption has been associated consistently with decreased fecundity (9). An Oxford Family Planning Association study observed a return to normal fecundity in ex-smokers (10). The reversible nature of the effect supports a dose-dependent relationship between smoking and infertility and also provides an important educational and motivational tool that may help to convince current smokers to stop.
Smoking and Infertility

Several comprehensive reviews have summarized the cumulative data on cigarette smoking and female fecundity and all support the conclusion that smoking has an adverse impact (4, 5, 12, 18–20). However, because the available studies are largely observational and include diverse populations, there is considerable potential for bias from multiple sources (4, 5).

A meta-analysis identified the pertinent literature available from Medline and Embase databases from 1966 through late 1997 and included 12 studies meeting strict inclusion criteria (5). Data from 10,928 exposed women and 19,179 unexposed women were entered into these analyses. The study yielded an overall OR and 95% confidence interval (CI) for infertility in smoking compared with nonsmoking women across all studies designs of 1.60 (CI 1.34–1.91). In cohort studies, the OR for conception delay over one year in smoking versus nonsmoking women was 1.42 (CI 1.27–1.58), and in case-control studies, the OR for infertility versus fertility in smokers compared with nonsmokers was 2.27 (CI 1.28–4.02). The narrow CI suggests that the summary OR is a reasonably accurate estimate of the effect and that the results are unlikely to have arisen by chance. Most of the studies excluded from the meta-analysis also support the findings that the prevalence of infertility is higher, fecundity is lower, and the time to conception is increased in smokers compared with nonsmokers. In some studies, the effects on fertility were seen only in women smoking more than 20 cigarettes per day, but a trend for all levels of smoking was identified.

Furthermore, a large scale population-based study demonstrated that smoking negatively affects fecundity, independent of other factors (21). The investigators studied data from nearly 15,000 pregnancies to determine time to conception. In addition to smoking, factors such as parental age, ethnicity, education, employment, housing, pre-pregnancy body mass index, and alcohol consumption were assessed for their possible confounding influences. Active smoking was associated with increased failure to conceive within both 6- and 12-month durations of study. Increasing delay to conception correlated with increasing daily numbers of cigarettes smoked. The percentage of women experiencing conception delay for over 12 months was 54% higher for smokers than for nonsmokers. Active smoking by either partner had adverse effects, and the impact of passive cigarette smoke exposure alone was only slightly smaller than for active smoking by either partner (21).

Ovarian Follicular Depletion

Menopause occurs one to four years earlier in smoking women than in nonsmokers (15–17). The dose-dependent nature of the effect supports the contention that smoking may accelerate ovarian follicular depletion. Chemicals in cigarette smoke appear to accelerate follicular depletion and the loss of reproductive function (15). Mean basal follicle-stimulating hormone (FSH) levels are significantly higher in young smokers than in nonsmokers (22, 23). In one study, basal FSH levels were 66% higher in active smokers than in nonsmokers and 39% higher in passive smokers than in nonsmokers (23). Urinary estrogen excretion during the luteal phase in smokers is only about one-third that observed in nonsmokers (24), possibly because constituents of tobacco smoke inhibit granulosa cell aromatase (25). Current smoking is also associated with lower anti-müllerian hormone (AMH) levels in late reproductive age and perimenopausal women (26).

Mean gonadotropin dose requirements for smokers receiving stimulation for in vitro fertilization (IVF) are higher when compared with those of nonsmoking women (24). The higher prevalence of abnormal clomiphene citrate challenge test (CCCT) results in smokers than in age-matched nonsmokers further provides evidence that smoking has adverse effects on ovarian reserve (27).
Effects on Sperm Parameters

The effect of smoking on male fertility is more difficult to discern. The effects of smoking and passive smoke on various semen parameters have been evaluated (4, 19, 21, 28–32). Reductions in sperm density, motility, antioxidant activity, and a possible adverse effect on morphology have been demonstrated (12, 33). The decrease in sperm concentration averaged 22% and was dose-dependent. Use of smokeless tobacco also has a dose-dependent negative effect on multiple semen parameters (34). Although sperm concentrations, motility, and/or morphology often are reduced compared with results observed in nonsmokers, they often remain within the normal range. However, the available evidence suggests that smoking may have adverse effects on sperm function based on a study involving the zona-free hamster egg penetration test (35). The available data do not demonstrate conclusively that smoking decreases male fertility (4, 19–21, 30, 36). Few studies have or can address the question, because of the confounding effects of partner smoking habits and fecundity.

Mutagenic Potential

Gametogenesis appears to be vulnerable to damage from tobacco smoke (37). Both chromosomal and DNA damage to human germ cells may result from tobacco smoke exposure (38). The proportion of diploid oocytes in the ovary increases with the number of cigarettes smoked per day (P<.001), an observation suggesting that smoking may disrupt function of the meiotic spindle in humans (38). Moreover, smoking in pregnant women is associated with an increased risk of trisomy 21 offspring resulting from maternal meiotic nondisjunction (39). The prevalence of Y chromosome disomy (two homologous Y chromosomes) in sperm correlates with urinary cotinine concentrations, a marker of recent exposure to cigarette smoke (40).

Evidence suggests that gene damage in sperm may relate to direct binding of tobacco smoke constituents or their intermediates to DNA (41, 42). When bound to DNA, some of these chemical “adducts” represent premutational lesions. Cigarette smoke contains toxic oxygen reactive species that help produce adducts and are mutagenic in their own right. Nuclear DNA damage and mitochondrial and cytoskeletal aberrations have been shown to result directly from oxidative stress in gametes, likely in part via adduct formation. These mechanisms are supported by the finding of increased chemical adducts in embryos from smokers compared with nonsmokers, indicating transmission of modified DNA originating from parental smoking (43).

Gamete DNA damage may cause many of the recognized adverse reproductive effects of smoking such as increased miscarriages, accelerated onset of menopause, and reduced fecundity. Increases in birth defects variably have been reported among the offspring of smoking parents, but the teratogenic effects of cigarette smoke during pregnancy confound whether DNA damage in gametes may play a role (43).

Early Pregnancy Effects

Smoking is associated with an increase in spontaneous miscarriage in both natural and assisted-conception cycles (4, 44, 45). Five of seven heterogeneous studies (including the only prospective study) of natural conception in female smokers have found an increased miscarriage risk (5). In one study of inner-city women 14–39 years of age, smoking accounted for 16% of miscarriages (45). Mechanisms have not been completely elucidated. There are few data investigating chromosomal effects of smoking within abortus tissue, but the vasoconstrictive and antimetabolic properties of some components of cigarette smoke such as nicotine, carbon monoxide, and cyanide may lead to placental insufficiency and embryonic and fetal growth restriction and demise. However, smokeless tobacco also is associated with increased risk of pregnancy loss (46, 47), suggesting that nicotine alone is the predominant toxic component.

Smoking also has been associated with bacterial vaginosis (which in turn is associated with second-trimester miscarriage) and with preterm labor (19, 20, 48). The risk of multiple gestations also may be increased in smokers (28, 49). Although it is difficult to control for involvement of other lifestyle factors, an association between ectopic pregnancy and smoking also has been reported (12, 50). A case-control study identified a dose-related risk for ectopic pregnancy among smokers (39). Women who smoked more than 20 cigarettes daily had an OR for ectopic pregnancy of 3.4 (95% CI 1.4–8.6) compared with nonsmokers.

Pickup of the oocyte cumulus complex and ciliary beat frequency were found to be inhibited in hamster oviduct subjected to cigarette smoke in a perfusion chamber (51). These abnormalities may contribute to increased incidences of ectopic pregnancy and tubal infertility in smoking women.

Effects of Maternal Smoking on Male Progeny

An epidemiologic study to identify the cause of decreasing sperm counts in Danish versus Finnish men has suggested an effect of maternal smoking (52). After adjusting for confounding factors, men whose mothers had smoked more than 10 cigarettes per day had lower sperm densities than men with nonsmoking mothers. Paternal smoking was unrelated to semen parameters of the offspring. It is possible that these effects on male offspring could be mediated by cadmium or other contaminants of cigarette smoke. Together with a reduction in fecundity and early pregnancy effects, these effects on progeny may add substantially to the overall adverse reproductive burden from smoking.

Influence on Assisted Reproduction Outcomes

Ten retrospective and four prospective studies have been included in one or more of three meta-analyses that have examined the effects of smoking on the outcome of pregnancies achieved via in vitro fertilization (IVF) or gamete intrafallopian transfer (GIFT) (4, 5, 53). Most of these studies of assisted reproduction have low power and failed to adjust for confounders. Meta-analysis of nine of the studies identified an OR of 0.66 (95% CI 0.49–0.88) for conception among smokers undergoing IVF (5). Another meta-analysis of seven relevant studies in addition to the authors’ own prospective data yielded an OR of 1.79 (95% CI 1.24–2.59) for the quotient
of successful first IVF cycles for nonsmokers over smokers \(^{(42)}\); the result suggested that smokers require nearly twice the number of IVF cycles to conceive as nonsmokers.

The specific adverse effects of smoking on reproductive processes cannot be defined precisely because reported outcomes have been heterogeneous. Yet studies of IVF and GIFT have variously reported an increased gonadotropin requirement for ovarian stimulation, lower peak E2 levels, elevated testosterone, fewer oocytes retrieved, higher numbers of canceled cycles, thicker zona pellucida, lower implantation rates, and more cycles with failed fertilization in smokers compared with nonsmokers \((4, 23, 49, 53–57)\). No study has examined specifically the effects of cigarette smoking on ovulation induction outcomes. The detrimental effect of smoking becomes more detectable in older women undergoing treatment \((4, 27, 36, 58)\). The effects of smoking and advancing age may therefore synergize to accelerate the rate of oocyte depletion \((37)\).

Possible mechanisms of compromised oocyte quality include the presence of toxins derived from tobacco smoke in follicular fluid. The follicular fluid concentrations of the heavy metal cadmium \((29)\), a known ovarian toxin, are higher in smokers than in nonsmokers. Likewise, the concentrations of cotinine (a major metabolite of nicotine) in the follicular fluid aspirated from women at time of egg retrieval in IVF cycles relate directly to the number of cigarettes smoked \((13)\). All women known to be exposed to passive smoke in the home also had detectable follicular fluid cotinine levels, albeit at lower concentrations. Also concerning was the finding that 84% of women who reported themselves as nonsmokers with nonsmoking partners had detectable levels of cotinine in their follicular fluids \((29)\). These women were exposed environmentally, with all but one working outside the home. These data emphasize the potential hazards from passive tobacco smoke inhalation.

A more recent study not included in the meta-analyses also concluded that smoking has adverse effects on conception rates in assisted reproduction treatment (ART) cycles \((49)\). Uniquely, this was a five-year prospective study that controlled for potential confounders to the effects of smoking and analyzed the quantity, frequency, and duration of smoking exposure among 221 couples. A dose-response effect for number of cigarettes smoked could not be demonstrated but was apparent for the duration of smoking. If a woman ever smoked during her lifetime, her risk of failing to conceive via ART more than doubled (relative risk = 2.5, 95% CI 1.38–4.55, \(P<.01\)). Each year that a woman smoked was associated with a 9% increase in the risk of unsuccessful ART cycles (95% CI 1.02–1.15, \(P<.01\)).

Overall, it appears that ART may not necessarily be able to overcome the reduction in natural fecundity associated with smoking.

**SMOKING CESSATION**

Unfortunately, even among pregnant women who may understand the risks of smoking, concerted efforts to help them quit smoking have been only modestly effective \((2)\). Smoking cessation rates generally are better for infertile women than for pregnant women. The only study to examine smoking cessation in infertile women found that a relatively simple and inexpensive approach based on individualized counseling regarding the risks of smoking was reasonably effective, increasing the proportion of women who quit smoking from 4% at baseline to 24% after 12 months of intervention \((3)\). This study method involved several minutes of counseling, education, and encouragement during each clinic visit, according to the patient’s individual stage of readiness to quit. This method was more successful than just providing educational materials and website addresses alone \((3)\).

In general populations, various interventions including behavior modification, group counseling, feedback, advice, and nicotine weaning with patches and gum have proven effective. However, only 5% of women referred to a specialty smoking cessation clinic actually attended. Regularly scheduled office visits and use of multiple interventions are more effective, albeit resource-intensive. In infertile women, carbon monoxide (CO) monitoring using an inexpensive hand-held spirometer also may be of benefit. Results correlate well with the self-reported number of cigarettes smoked and offer feedback to patients. Serum and urine cotinine concentrations also have been used effectively for the same purpose \((20, 59)\).

The Public Health Service and National Cancer Institute offer validated office-based intervention guidelines for smoking cessation that incorporate and extend the above-described recommendations \((60, 61)\). A five-step approach is suggested: 1) Ask about smoking at every opportunity; 2) Advise all smokers to stop; 3) Assess willingness to stop; 4) Assist patients in stopping (including the use of pharmaceuticals and CO monitoring); and 5) Arrange followup visits \((19, 35)\). Specific smoking-cessation protocols for pregnant women have been outlined in several recent reviews \((2, 30, 62)\). Other helpful resources for smoking cessation for health-care providers and patients are available from various organizations (Centers for Disease Control, American Cancer Association) via their websites.

Although medical adjunctive therapy for smoking cessation has not been studied in infertile women, it may be justified for some. When behavioral approaches fail, the use of nicotine replacement therapy (NRT) and/or bupropion has resulted in a two-fold increase in the proportion of non-pregnant women able to quit smoking \((59)\).

Available medical therapies include NRT in the form of gum and patches (both available over the counter) as well as nasal sprays and inhalers. Because the latter two have not been studied in pregnancy and are classified as category D agents (there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans), NRT via nasal inhalers and sprays are best avoided in pregnant women and women attempting to conceive. Nicotine gum carries a category C classification and the nicotine patch is a category D agent, despite its reported safety in the limited clinical studies involving pregnant women that have been conducted to date.

The only non-nicotine Food and Drug Administration (FDA)-approved smoking cessation agent is the aminoketone bupropion (Zyban, GlaxoSmithKline) Bupropion is also available for use as an antidepressant (Wellbutrin, GlaxoSmithKline) but is marketed differently (Zyban).
cessation with a category B classification. The efficacy of bupropion appears similar to that of NRT strategies. Although studies of both bupropion and NRT in pregnant women have been limited, no adverse effects for pregnant women or their fetuses have been reported thus far. Ideally, however, pharmaceutical smoking cessation therapies are best used prior to conception.

When the likelihood of achieving smoking cessation is high and its benefits appear to outweigh the combined risks of smoking and NRT in pregnant or potentially pregnant women, NRT may be reasonable. The nicotine levels that result from daily inhalation of 10 or more cigarettes are higher than those associated with recommended doses of nicotine gum and patches (59). Eliminating the exposure to the many other chemicals contained in cigarette smoke is one clear advantage of NRT (2). No studies have directly compared bupropion and NRT in infertile or pregnant women. However, given the relative safety and generally good compliance with prescribed bupropion treatment, it would appear to be an acceptable initial medical intervention, when needed.

On average, female smokers referred for evaluation and treatment of infertility have tried to quit smoking three times previously. Sadly, only 18% of such women have received advice on smoking cessation from their referring physicians (3). The likelihood of achieving smoking cessation appears to increase with each attempt (20, 62), and physicians who care for infertile women have another opportunity to help them quit smoking, beginning with their initial visit.

The substantial reproductive risks associated with smoking and the revelation that much of the reduced fecundity associated with smoking may be reversed within a year of cessation (3, 4, 10, 63) can be powerful incentives when included in physician counseling. When successful, smoking cessation represents an important part of effective treatment for infertility.

### SUMMARY

- Available biologic, experimental, and epidemiological data indicate that up to 13% of infertility may be attributable to cigarette smoking.
- Smoking appears to accelerate the loss of reproductive function and may advance the time of menopause by 1 to 4 years.
- There is good evidence that semen parameters and results of sperm function tests are 22% poorer in smokers than in nonsmokers and the effects are dose-dependent, but smoking has not yet been conclusively shown to reduce male fertility.
- There is evidence that smoking is associated with increased risks of spontaneous abortion and ectopic pregnancy.
- Gamete mutagenesis is one possible mechanism whereby smoking may adversely affect fecundity and reproductive performance.
- There is good evidence that smokers require nearly twice the number of IVF attempts to conceive as nonsmokers.
- The adverse effects of sidestream and passive smoking are now established, and there is good evidence that nonsmokers with excessive exposure to tobacco smoke may have reproductive consequences as great as those observed in smokers.
- Clinicians can facilitate smoking cessation by providing education, monitoring, and consistent individualized support.

### CONCLUSION

The accumulated evidence supports the value of taking a preventive approach to infertility by discouraging smoking and helping to eliminate exposure to tobacco smoke in both women and men.

**Acknowledgments:** This report was developed under the direction of the Practice Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Practice Committee and the Board of Directors of the American Society for Reproductive Medicine have approved this report.

The following members of the ASRM Practice Committee participated in the development of this document. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document. Samantha Pfeifer, M.D.; Marc Fritz, M.D.; Jeffrey Goldberg, M.D.; R. Dale McClure, M.D.; Michael Thomas, M.D.; Eric Widra, M.D.; Glenn Schattman, M.D.; Mark Licht, M.D.; John Collins, M.D.; Marcelle Cedars, M.D.; Catherine Racowsky, Ph.D.; Owen Davis, M.D.; Kurt Barnhart, M.D., M.S.C.E.; Clarisa Gracia, M.D., M.S.C.E.; William Catherino, M.D., Ph.D.; Robert Rebar, M.D.; Andrew La Barbera, Ph.D.

### REFERENCES


